Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | ALB | P02768 | 2/20 | 0.58 |
| ▸ | BLM | P54132 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | TK1 | P04183 | 7/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8920703 | 1.00 | LMNA (0.58) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL13286394 | 1.00 | LMNA (0.58) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL27505365 | 1.00 | LMNA (0.58) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL23485 | 1.00 | LMNA (0.58) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL925743 | 1.00 | LMNA (0.58) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL29711774 | 1.00 | LMNA (0.58) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL14421795 | 1.00 | LMNA (0.58) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL762579 | 1.00 | LMNA (0.58) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL22992337 | 1.00 | LMNA (0.58) | LMNAALBBLMALDH1A1POLB | |
| Methane SCHEMBL25262791 | 0.99 | TK1 (0.57) | LMNAALBBLMALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023178133-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| EP-4234566-A1 | MODIFIED NUCLEOSIDE OR NUCLEOTIDE | BGI Shenzhen (CN) | 2023-08-30 | — | — | EP | disclosed |
| US-20220195437-A1 | TAU-TARGETING OLIGONUCLEOTIDE GAPMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-23 | — | — | US | disclosed |
| WO-2017201585-A1 | MODULATORS OF DUX4 FOR REGULATION OF MUSCLE FUNCTION | GENEA IP HOLDINGS PTY LTD (AU) | 2017-11-30 | — | — | WO | disclosed |
| EP-3126512-A2 | PHOTO-SELECTIVE METHOD FOR BIOLOGICAL SAMPLE ANALYSIS FIELD | Ventana Medical Systems, Inc. (US) | 2017-02-08 | — | — | EP | disclosed |
| EP-3028707-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES | Ophthotech Corporation (US) | 2016-06-08 | — | — | EP | disclosed |
| WO-2015128272-A2 | PHOTO-SELECTIVE METHOD FOR BIOLOGICAL SAMPLE ANALYSIS FIELD | VENTANA MEDICAL SYSTEMS, INC. (US) | 2015-09-03 | — | — | WO | disclosed |
| WO-2013090420-A2 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
| US-20070015733-A1 | Aryl Phosphate Derivatives of d4T having Activity Against Resistant HIV Strains | PARKER HUGHES INSTITUTE (US) | 2007-01-18 | — | — | US | disclosed |
| US-20070015733-A1 | Aryl Phosphate Derivatives of d4T having Activity Against Resistant HIV Strains | PARKER HUGHES INSTITUTE (US) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015733-A1 | Aryl Phosphate Derivatives of d4T having Activity Against Resistant HIV Strains | TYMP, PNP, APRT | LMNA 4490/4885ALB 3615/4885BLM 4318/4885 |
| US-20220195437-A1 | TAU-TARGETING OLIGONUCLEOTIDE GAPMERS | MAPT, GAP43, RNMT | LMNA 1392/4885ALB 4034/4885BLM 3835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.